BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

164 related articles for article (PubMed ID: 33993526)

  • 1. Injectable opioid agonist treatment: An evolutionary concept analysis.
    Haines M; O'Byrne P
    Res Nurs Health; 2021 Aug; 44(4):664-671. PubMed ID: 33993526
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Service delivery models for injectable opioid agonist treatment in Canada: 2 sequential environmental scans.
    Eydt E; Glegg S; Sutherland C; Meador K; Trew M; Perreault M; Goyer MÈ; Le Foll B; Turnbull J; Fairbairn N
    CMAJ Open; 2021; 9(1):E115-E124. PubMed ID: 33622764
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Measuring the preferences of injectable opioid agonist treatment (iOAT) clients: Development of a person-centered scale (best-worst scaling).
    Dobischok S; Metcalfe R; Matzinger E; Palis H; Marchand K; Harrison S; MacDonald S; Byres D; Schechter M; Bansback N; Oviedo-Joekes E
    Int J Drug Policy; 2023 Feb; 112():103948. PubMed ID: 36586152
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Expanding access to diacetylmorphine and hydromorphone for people who use opioids in Canada.
    Maghsoudi N; Bowles J; Werb D
    Can J Public Health; 2020 Aug; 111(4):606-609. PubMed ID: 32221867
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Take home injectable opioids for opioid use disorder during and after the COVID-19 Pandemic is in urgent need: a case study.
    Oviedo-Joekes E; MacDonald S; Boissonneault C; Harper K
    Subst Abuse Treat Prev Policy; 2021 Mar; 16(1):22. PubMed ID: 33673847
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Injectable opioid agonist treatment for opioid use disorder: a national clinical guideline.
    Fairbairn N; Ross J; Trew M; Meador K; Turnbull J; MacDonald S; Oviedo-Joekes E; Le Foll B; Goyer MÈ; Perreault M; Sutherland C
    CMAJ; 2019 Sep; 191(38):E1049-E1056. PubMed ID: 31548191
    [No Abstract]   [Full Text] [Related]  

  • 7. Perceptions of injectable opioid agonist treatment (iOAT) among people who regularly use opioids in Australia: findings from a cross-sectional study in three Australian cities.
    Nielsen S; Sanfilippo P; Belackova V; Day C; Silins E; Lintzeris N; Bruno R; Grebely J; Lancaster K; Ali R; Bell J; Dietze P; Degenhardt L; Farrell M; Larance B
    Addiction; 2021 Jun; 116(6):1482-1494. PubMed ID: 33067836
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Exploring Patients' Perceptions on Injectable Opioid Agonist Treatment: Influences on Treatment Initiation and Implications for Practice.
    Friedmann Z; Binder A; Kinkel HT; Kühner C; Zsolnai A; Mick I
    Eur Addict Res; 2024; 30(1):32-42. PubMed ID: 38104539
    [TBL] [Abstract][Full Text] [Related]  

  • 9. High Interest in Injectable Opioid Agonist Treatment With Hydromorphone Among Urban Syringe Service Program Participants.
    Fox AD; Riback L; Perez-Correa A; Ohlendorf E; Ghiroli M; Behrends CN; López-Castro T
    Subst Use Addctn J; 2024 Jan; 45(1):44-53. PubMed ID: 38258851
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cost-effectiveness of hydromorphone for severe opioid use disorder: findings from the SALOME randomized clinical trial.
    Bansback N; Guh D; Oviedo-Joekes E; Brissette S; Harrison S; Janmohamed A; Krausz M; MacDonald S; Marsh DC; Schechter MT; Anis AH
    Addiction; 2018 Jul; 113(7):1264-1273. PubMed ID: 29589873
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Men's and women's response to treatment and perceptions of outcomes in a randomized controlled trial of injectable opioid assisted treatment for severe opioid use disorder.
    Palis H; Marchand K; Guh D; Brissette S; Lock K; MacDonald S; Harrison S; Anis AH; Krausz M; Marsh DC; Schechter MT; Oviedo-Joekes E
    Subst Abuse Treat Prev Policy; 2017 May; 12(1):25. PubMed ID: 28526048
    [TBL] [Abstract][Full Text] [Related]  

  • 12. "As long as that place stays open, I'll stay alive": Accessing injectable opioid agonist treatment during dual public health crises.
    Jaffe K; Blawatt S; Lehal E; Lock K; Easterbrook A; MacDonald S; Harrison S; Lajeunesse J; Byres D; Schechter M; Oviedo-Joekes E
    Harm Reduct J; 2023 Apr; 20(1):51. PubMed ID: 37060027
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Patterns of use and adverse events reported among persons who regularly inject buprenorphine: a systematic review.
    Bozinoff N; Tardelli VS; Rubin-Kahana DS; Le Foll B
    Harm Reduct J; 2022 Oct; 19(1):113. PubMed ID: 36229831
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Can Treatment for Substance Use Disorder Prescribe the same Substance as that Used? The Case of Injectable Opioid Agonist Treatment.
    Steel D; Tekin Ş
    Kennedy Inst Ethics J; 2021; 31(3):271-301. PubMed ID: 34565745
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Hydromorphone Compared With Diacetylmorphine for Long-term Opioid Dependence: A Randomized Clinical Trial.
    Oviedo-Joekes E; Guh D; Brissette S; Marchand K; MacDonald S; Lock K; Harrison S; Janmohamed A; Anis AH; Krausz M; Marsh DC; Schechter MT
    JAMA Psychiatry; 2016 May; 73(5):447-55. PubMed ID: 27049826
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Safety profile of injectable hydromorphone and diacetylmorphine for long-term severe opioid use disorder.
    Oviedo-Joekes E; Brissette S; MacDonald S; Guh D; Marchand K; Jutha S; Harrison S; Janmohamed A; Zhang DZ; Anis AH; Krausz M; Marsh DC; Schechter MT
    Drug Alcohol Depend; 2017 Jul; 176():55-62. PubMed ID: 28521199
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Characteristics and response to treatment among Indigenous people receiving injectable diacetylmorphine or hydromorphone in a randomised controlled trial for the treatment of long-term opioid dependence.
    Oviedo-Joekes E; Palis H; Guh D; Marchand K; Brissette S; Lock K; MacDonald S; Harrison S; Anis AH; Krausz M; Marsh DC; Schechter MT
    Drug Alcohol Rev; 2018 Jan; 37(1):137-146. PubMed ID: 28593748
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Building healthcare provider relationships for patient-centered care: A qualitative study of the experiences of people receiving injectable opioid agonist treatment.
    Marchand K; Foreman J; MacDonald S; Harrison S; Schechter MT; Oviedo-Joekes E
    Subst Abuse Treat Prev Policy; 2020 Jan; 15(1):7. PubMed ID: 31959189
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Perinatal Injectable Opioid Agonist Therapy (iOAT) Administration: A Case Series.
    Patricelli CJ; Chai J; Gordon S; Gouin IJ; Carter N; Stewart K; Paquette V; Urbanoski K; Albert A
    J Addict Med; 2023 Jul-Aug 01; 17(4):431-438. PubMed ID: 37579103
    [TBL] [Abstract][Full Text] [Related]  

  • 20. "I'm just searching to get better": Constructions of treatment citizenship on injectable opioid agonist treatment.
    Mayer S; Jenkins E; Fairbairn N; Fowler A; McNeil R
    Soc Sci Med; 2024 May; 348():116708. PubMed ID: 38531216
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.